Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/57674
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJean Marc Steensen_US
dc.contributor.authorDidier Scherreren_US
dc.contributor.authorPaul Ginesteen_US
dc.contributor.authorP. Noel Barretten_US
dc.contributor.authorSupparatpino Khuanchaien_US
dc.contributor.authorRatanasuwan Winaien_US
dc.contributor.authorKiat Ruxrungthamen_US
dc.contributor.authorJamal Tazien_US
dc.contributor.authorRobert Murphyen_US
dc.contributor.authorHartmut Ehrlichen_US
dc.date.accessioned2018-09-05T03:47:52Z-
dc.date.available2018-09-05T03:47:52Z-
dc.date.issued2017-07-01en_US
dc.identifier.issn10986596en_US
dc.identifier.issn00664804en_US
dc.identifier.other2-s2.0-85021658372en_US
dc.identifier.other10.1128/AAC.00545-17en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021658372&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/57674-
dc.description.abstractCopyright © 2017 Steens et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. We investigated the safety and antiviral effects of an anti-HIV compound (ABX464) with a unique mechanism of viral replication inhibition. This was a randomized, double-blind, placebo-controlled, dose-ranging study in treatment-naive HIV-infected patients. Participants were assigned to eight groups; each group included eight subjects receiving either the study compound, ABX464 (n 6), or the corresponding placebo (n 2), according to a randomization code. The first dose administered was 25 mg, given once or 3 times a day over a 2- to 3-week period. Ascending doses of up to 150 mg were delivered after review of the safety data. The primary objective of the study was to assess the safety and tolerability of ABX464 after repeated oral administrations in subjects infected by HIV. Sixty-six subjects were enrolled and were randomized. Sixty-three subjects completed the study according to the study protocol. Twenty-one adverse events (AEs) were reported by 7 subjects out of 16 (44%) who received placebo, and 158 AEs were reported by 39 subjects out of 50 (78%) who received the study drug. In the ABX464 treatment group, all of these adverse events were mild to moderate. No subjects discontinued treatment due to drug-related AEs. Administration of ABX464 at up to 150 mg once a day was safe and well tolerated in HIV-infected subjects. An efficacy signal with respect to a reduction of the viral load by ABX464 was detected, mainly in subjects treated at the highest dose. Further studies will be required to demonstrate antiviral effects in HIV-infected subjects in combination with other antiretroviral therapies. (This study is registered on the ClinicalTrials.gov website under registration no. NCT02452242.).en_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleSafety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled studyen_US
dc.typeJournalen_US
article.title.sourcetitleAntimicrobial Agents and Chemotherapyen_US
article.volume61en_US
article.stream.affiliationsAbivaxen_US
article.stream.affiliationsIndependent Consultanten_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsMahidol Universityen_US
article.stream.affiliationsChulalongkorn Universityen_US
article.stream.affiliationsIGMM Institut de Genetique Moleculaire de Montpellieren_US
article.stream.affiliationsNorthwestern University Feinberg School of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.